Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer

被引:82
作者
Winder, Thomas [1 ]
Lenz, Heinz-Josef [1 ,2 ]
机构
[1] Univ So Calif, Keck Sch Med, Div Med Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[2] Univ So Calif, Keck Sch Med, Dept Prevent Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA
关键词
EGFR-Pathway; VEGF-Pathway; Targeted Treatment; PHASE-II TRIAL; CETUXIMAB PLUS IRINOTECAN; TYROSINE KINASE INHIBITOR; CELL LUNG-CANCER; FACTOR-RECEPTOR; 1ST-LINE TREATMENT; TUMOR-GROWTH; PANITUMUMAB MONOTHERAPY; ANTI-VEGF; K-RAS;
D O I
10.1053/j.gastro.2010.02.005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Treatment of colorectal cancer (CRC) has developed considerably over the past decade, especially in the areas of targeted therapeutics and biomarker development. Multiple cellular pathways influence the growth and metastatic potential of CRC. Targeted therapies have been designed to interfere with specific molecular events in pathways that mediate tumor growth and progression. Preclinical and clinical studies have shown that the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are valid therapeutic targets for patients with CRC. Monoclonal antibodies and tyrosine kinase inhibitors have been developed to target EGFR, VEGF, and VEGF receptors (VEGFRs) and are important additions to CRC treatment options. We review the most recent data on the VEGF and EGFR signaling pathways and therapeutic reagents designed to target them, provide insights into their mechanisms, and describe results from recent clinical trials.
引用
收藏
页码:2163 / 2176
页数:14
相关论文
共 97 条
[1]   Eph receptors and ephrin ligands: Essential mediators of vascular development [J].
Adams, RH ;
Klein, R .
TRENDS IN CARDIOVASCULAR MEDICINE, 2000, 10 (05) :183-188
[2]  
Albanell J, 2001, SEMIN ONCOL, V28, P56, DOI 10.1053/sonc.2001.28551
[3]   Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer [J].
Allegra, Carmen J. ;
Yothers, Greg ;
O'Connell, Michael J. ;
Sharif, Saima ;
Colangelo, Linda H. ;
Lopa, Samia H. ;
Petrelli, Nicholas J. ;
Goldberg, Richard M. ;
Atkins, James N. ;
Seay, Thomas E. ;
Fehrenbacher, Louis ;
O'Reilly, Seamus ;
Chu, Luis ;
Azar, Catherine A. ;
Wolmark, Norman .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3385-3390
[4]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[5]  
[Anonymous], J CLIN ONCOL S
[6]  
[Anonymous], 2007, J CLIN ONCOL S
[7]   Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients [J].
Bajetta, Emilio ;
Di Bartolomeo, Maria ;
Buzzoni, Roberto ;
Ferrario, Erminia ;
Dotti, Katia F. ;
Mariani, Luigi ;
Bajetta, Roberto ;
Gevorgyan, Arpine ;
Venturino, Paola ;
Galassi, Margherita .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (01) :67-72
[8]   Somatic mutations of EGFR in colorectal cancers and glioblastomas [J].
Barber, TD ;
Vogelstein, B ;
Kinzler, KW ;
Velculescu, VE .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27) :2883-2883
[9]   Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].
Baselga, J ;
Rischin, D ;
Ranson, M ;
Calvert, H ;
Raymond, E ;
Kieback, DG ;
Kaye, SB ;
Gianni, L ;
Harris, A ;
Bjork, T ;
Averbuch, SD ;
Feyereislova, A ;
Swaisland, H ;
Rojo, F ;
Albanell, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302
[10]   Tumorigenesis and the angiogenic switch [J].
Bergers, G ;
Benjamin, LE .
NATURE REVIEWS CANCER, 2003, 3 (06) :401-410